Commentary: Pediatric antifungal drug development: Lessons learned and recommendations for the future

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 635-637

  Watt, Kevin M ^a   Cohen Wolkowiez, Michael ^a   Ward, Robert M ^b   Benjamin Jr , Daniel K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; MICAFUNGIN; VORICONAZOLE;

ADOLESCENT DISEASE; CHILDHOOD DISEASE; DRUG EXPOSURE; DRUG LEGISLATION; ENCEPHALITIS; HEALTH CARE POLICY; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; MALE;

EID: 84861528135     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824f8426     Document Type: Review

References (24)

1. Undre NA, Stevenson P, Freire A, et al. Pharmacokinetics of Micafungin in Pediatric Patients with Invasive Candidiasis and Candidemia. Pediatr Infect Dis J. 2012;31:630-632.
2. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
3. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
4. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145-1152.
5. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93-99.
6. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412-415.
7. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(suppl 1):10-16.
8. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54:4116-4123.
9. Doby EH, Benjamin DK Jr, Blaschke AJ, et al. Therapeutic Monitoring of Voriconazole in Children Less Than 3 Years of Age: A Case Report and Summary of Voriconazole Concentrations for 10 Children. Pediatr Infect Dis J. 2012;31:632-635.
10. Andes D, Diekema DJ, Pfaller MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54:2497-2506.
11. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48:137-142.
12. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165-3169.
13. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:1193-1199.
14. Andes D, Safdar N, Marchillo K, et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50:674-684.
15. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45:922-926.
16. Andes D, van Ogtrop M. Characterization and quantitation of thepharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43:2116-2120.
17. Andes D, Forrest A, Lepak A, et al. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother. 2006;50:2374-2383.
18. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
19. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
20. Wynn JL, Tan S, Gantz MG, et al.; NICHD Neonatal Research Network. Outcomes following candiduria in extremely low birth weight infants. Clin Infect Dis. 2012;54:331-339.
21. Phillips JR, Karlowicz MG. Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit. Pediatr Infect Dis J. 1997;16:190-194.
22. Chun CS, Turner RB. The outcome of candiduria in pediatric patients. Diagn Microbiol Infect Dis. 1991;14:119-123.
23. Hurley R, Winner HI. Experimental renal moniliasis in the mouse. J Pathol Bacteriol. 1963;86:75-82.
24. Hughes WT. Systemic candidiasis: a study of 109 fatal cases. Pediatr Infect Dis. 1982;1:11-18.